The Weekly Pulse — Edition 23 · March 1, 2026

Published · Researched 2026-09-22

The week in one paragraph

Two personalized mRNA cancer vaccines landed in the same week, and both results are hard to look away from. In a small Phase 1 pancreatic cancer trial, six of eight patients whose immune systems responded to a custom-built mRNA vaccine were cancer-free at a median 3.2 years — and later reporting had seven of eight alive four to six years after surgery, in a disease where long-term survival is almost unheard of. Meanwhile, a randomized Phase 2b trial of Moderna and Merck's personalized mRNA-4157 (V940) plus Keytruda cut melanoma recurrence-or-death risk by 44% versus Keytruda alone, with 18-month recurrence-free survival at 78.6% against 62.2%. Each dose is built from the patient's own tumor mutations — up to 34 neoantigens — a prescription written for one person at a time. Both remain investigational. Still watching: the pancreatic figures rest on a news summary of the study and a tiny cohort — signal, not proof — and V940's larger Phase 3 program is the real test.

Rising

Five years of not looking away. Plainview, New York's 5th Annual Rally for Rebecca 5K pushed five years of community giving past $1 million for Rebecca Koltun, 26, paralyzed from the neck down since a 2021 skiing accident. Her care costs exceed $200,000 a year — specialized round-the-clock care, a custom wheelchair, an accessible van — and thousands of neighbors, schools, and businesses have refused to let the family face it alone.
The Wilds welcomes its second 2026 calf. A female southern white rhino calf was born March 28 to mother Kali at the Ohio conservation center, with mother and calf reported to be doing well and bonding. Still watching: the calf's name and further development milestones were not in the material reviewed.
Marlene gets her keys. The Avangrid Foundation joined Greater Rochester Habitat for Humanity to celebrate a new Habitat home for Marlene's family — a completed build, announced September 22, 2026, the same day the research confirmed its recency. A Facebook video documented the celebration. Still watching: social verification is provisional — the video's specific URL was not preserved.

Falling

Pancreatic cancer's near-certain relapse cracked, at least in a small cohort — six of eight responders cancer-free past three years is an outcome this disease almost never produces.
Melanoma's recurrence odds took a hit too: a 44% risk reduction is the strongest clinical signal yet that personalized mRNA vaccines can work in humans.

Quiet signals

V940's social layer is oncology media, not patients. Targeted Threads searches turned up posts about an unrelated Russian mRNA program, not Moderna/Merck's trial — the story is real but its social footprint is still professional press. Watch for patient voices as Phase 3 advances.
The pancreatic story's social echo is thin too. It circulated via a science magazine's Threads post linking its coverage — worth tracking whether it breaks into broader patient communities.
The rhino program bears watching. Two 2026 calves at one facility is a breeding-program signal — track whether The Wilds sustains this pace.

Scoreboard

N/A — editions are being written out of sequence, so there are no prior calls to grade.

One line to close

Medicine is learning to write a prescription for one person at a time — and this week, it worked twice.